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http://dx
888Objective(s): Previous studies have shown that individual risk factors are poor predictors of mortality after heart
transplantation in patients with congenital heart disease. We developed composite risk factor groups to better
predict mortality after cardiac transplantation.
Methods: We conducted a cross-sectional retrospective analysis of all heart transplants performed for
congenital heart disease at a single congenital heart transplant center between 1996 and 2011. Patient,
procedural, and hospital course data were obtained through a review of medical records. Univariate analyses
were performed using the Fisher exact test for categorical data and the Mann-Whitney U test for continuous
variables. Overall mortality was examined using Kaplan-Meier estimates for univariate analysis and Cox
regression analysis for multivariate analysis. A comparison of patients with functional single ventricles (SVs)
versus biventricular (BV) hearts was performed. Mean follow-up duration for the whole group was 51  43
months (median, 43 months).
Results: Forty-six patients underwent heart transplantation during the study period. Mean age at transplant was
9.0 9.1 years; 45% (n¼ 21) were in the SV group and 55% (n¼ 25) were in the BV group. The SV group had
significantly more previous sternotomies (P ¼ .006) and longer bypass times (266  78 vs 207  64
minutes; P ¼ .001). High panel-reactive antibody levels (>10%) were also more common in the SV
group (38% vs 13%; P¼ .08). Overall hospital mortality was 4.3% (n¼ 2, both SVs). There was no significant
difference in operative mortality (10% SV vs 0% BV; P ¼ .20) or major morbidity (33% SV vs 44% BV;
P¼ .51) between the 2 groups. High-risk groups identified by univariate analysis were patients with an SV diag-
nosis þ dialysis (P< .0005), SV þ mechanical assist device (VAD)/extracorporeal membrane oxygenation
(ECMO) (P ¼ .026), or VAD/ECMO þ renal insufficiency (P ¼ .006)/VAD/ECMO þ dialysis (P<.0005),
and SV þ reoperation (P ¼ .016). By multivariate analysis, preoperative renal insufficiency (P ¼ .038) and
the composite SV þ dialysis (P ¼ .005) were predictors of overall mortality. Although survival at 2 years
was lower in the SV cohort (73% vs 96%; P ¼ .16), this benefit was not apparent (63% vs 69%) at late
follow-up.
Conclusions: Preoperative renal insufficiency and SV þ dialysis are strong predictors of overall mortality and
identify high-risk congenital heart transplant recipients. Although individual risk factors may not predict sur-
vival, a composite of factors may be more useful in identifying the high-risk recipient. (J Thorac Cardiovasc
Surg 2013;146:888-93)Rapid strides have been made in the surgical reconstruction
and postoperative care of patients with congenital heart
disease (CHD), particularly neonates with complex de-
fects.1 Despite these advances, many children with complex
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These patients have commonly undergone multiple proce-
dures and are known to be at a higher risk for postoperative
death and complications after transplantation.2,3 The supply
of pediatric organ donors is limited by strict donor-recipient
weight criteria, and is steadily decreasing,4 which makes
optimal organ allocation critical for the maintenance of
viable pediatric heart transplant programs.
The ability to reliably identify patients at high risk is
essential to optimize pediatric donor heart allocation.
Individual risk factors that are associated with poor
outcomes after heart transplant have been identified.5
However, it has been demonstrated that risk factors taken
individually are unable to reliably predict mortality after
heart transplant.6 A combination of risk factors may be
more accurate predictors of mortality after pediatric heartery c October 2013
TABLE 1. Patient demographics and risk factors in single-ventricle
versus biventricular congenital heart transplant patients
Variable SV (n ¼ 21) BV (n ¼ 25) P value
Age, y
Mean  SD 8  9 10  9 .208
Median 3 9
Range 0.05-28 0.42-35
Male sex 13 (62) 15 (60) 1.000
Race
White 12 (57) 14 (56) .403
Black 9 (43) 9 (36)
Other 0 (0) 2 (8)
Recipient weight, kg
Mean  SD 26  23 31  24 .396
Median 12 30
Range 4-69 3-95
Donor weight, kg
Mean  SD 27  21 41  27 .060
Median 18 32
Range 6-63 7-88
Donor/recipient weight ratio
Mean  SD 1.5  0.5 1.6  0.6 .308
Median 1.5 1.8
Range 0.8-2.5 0.7-3.0
Previous cardiac procedure 20 (95) 15 (60) .006
Total bilirubin, mg/dL
Mean  SD 1.6  1.3 1.7  2.7 .365
Median 1.1 0.9
Range 0.3-4.8 0.4-13.4
Creatinine, mg/dL
Mean  SD 0.7  0.8 0.7  0.5 .602
Median 0.5 0.6
Range 0.3-3.8 0.1-1.7
Ventilator dependent 6 (29) 8 (32) 1.000
Inotrope dependent 14 (67) 14 (56) .551
ECMO/VAD dependent 3 (14) 6 (24) .478
Dialysis dependent 2 (10) 1 (4) .585
PRA>10% 8 (38) 3 (13) .081
Data are given as number (%) unless otherwise indicated. SV, Single ventricle; BV,
biventricular; ECMO, extracorporeal membrane oxygenation; VAD, ventricular assist
device; PRA, panel-reactive antibody; SD, standard deviation.
Abbreviations and Acronyms
BIVAD ¼ biventricular assist device
BV ¼ biventricular
CHD ¼ congenital heart disease
ECMO ¼ extracorporeal membrane oxygenation
PRA ¼ panel-reactive antibody
SV ¼ single ventricle
UNOS ¼ United Network of Organ Sharing
VAD ¼ ventricular assist device
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outcome in multicenter studies do not seem to be accurate
predictors in single-center studies.2
We evaluated the outcomes of patients receiving a heart
transplant at a single center with the diagnosis of CHD.
We assessed established risk factors both individually and
in combination for their association with and ability to
predict outcome.
METHODS
Study Population
We conducted a cross-sectional retrospective analysis of all heart
transplants performed for congenital heart disease at the Medical
University of South Carolina (Charleston) Congenital Heart Transplant
Center between 1996 and 2011. This study received approval for
exemption from the Institutional Review Board of the Medical University
of South Carolina. Patient, procedural, and hospital course data were
obtained through a review of medical records.
Renal insufficiency was defined as a preoperative creatinine level of
1.5 mg/dL or higher and/or a need for preoperative dialysis. To identify
recipients who had a significant postoperative inotrope requirement,
postoperative inotropic support was defined as inotropes other than
milrinone and dopamine more than 48 hours posttransplant and was
quantified in days posttransplant for comparison between single-
ventricle (SV) and biventricular (BV) groups. This definition was selected
because many heart transplant recipients in our program remain on
low-dose dopamine for 3 to 4 days and milrinone for the first postopera-
tive week. Postoperative bleeding was defined as the need for
re-exploration. Postoperative infection was defined as a positive blood
culture or deep sternal wound infection requiring operative intervention.
Postoperative renal failure was defined as a creatinine level increase of
1.5 mg/dL or higher, with or without renal replacement therapy required
in the first postoperative week.
To compare morbidity rates in the SV versus BV group, we defined
major postoperative morbidity as a composite of postoperative cerebro-
vascular accident, important postoperative bleeding, renal failure,
postoperative infection, or grade 3 rejection. Mechanical support patients
received extracorporeal membrane oxygenation (ECMO) and/or ventri-
cular assist device (VAD) support before transplantation.
Data Analysis
Univariate analyses were performed using the Fisher exact test for
categorical data and the Mann-Whitney U test for continuous variables.
Mortality was examined at 1 month, 1 year, 3 years, 6 years, and overall
using Kaplan-Meier estimates for univariate analysis and Cox regression
analysis for multivariate analysis. A comparison of patients with functional
SVs versus BVs was performed. Mean follow-up duration for the whole
group was 51  43 months (median, 43 months).The Journal of Thoracic and CaRESULTS
Forty-six patients underwent heart transplantation during
the study period. Preoperative risk factors were evaluated
for the whole group (Table 1), and a comparison was
performed between SV and BV groups (Table 2). Mean
age at transplant was 9.0  9.1 years.
A total of 45% (n ¼ 21) were in the SV group and 55%
(n ¼ 25) were in the BV group. High panel-reactive
antibody (PRA) levels (>10%) were more common in the
SV group (38% vs 13%; P ¼ .08). The SV group had
significantly more previous sternotomies (P ¼ .006) and
longer bypass times (266  78 vs 207  64 minutes;
P ¼ .001). Eight patients received preoperative mechanical
support. Three patients in each group had ECMO.
Two patients in the BV group had Abiomed BVS 5000rdiovascular Surgery c Volume 146, Number 4 889
TABLE 2. Intraoperative and postoperative events in single-ventricle
and biventricular congenital heart transplant patients
Variable SV (n ¼ 21) BV (n ¼ 25) P value
Bypass time, min
Mean  SD 266  78 207  64 .001
Median 239 190
Range 172-511 140-375
Donor ischemic time, min
Mean  SD 266  42 262  47 .749
Median 272 263
Range 175-338 151-360
ICU length of stay, d
Mean  SD 24  47 10  7 .492
Median 9 8
Range 3-195 3-25
Hospital length of stay, d
Mean  SD 40  48 27  29 .309
Median 16 14
Range 8-195 10-107
Follow-up, mo
Mean  SD 48  50 54  37 .251
Median 30 45
Range 0.5-169 3-136
Postoperative inotropes 15 (71) 16 (64) .754
Postoperative bleeding 4 (19) 2 (8) .390
Postoperative infection 2 (10) 5 (20) .428
Postoperative CVA 1 (5) 1 (4) 1.000
Postoperative renal failure 4 (19) 6 (24) .735
Operative mortality 2 (10) 0 (0) .203
Postoperative major morbidity 7 (33) 11 (44) 1.000
Data are given as number (%) unless otherwise indicated. SV, Single ventricle; BV,
biventricular; ICU, intensive care unit; CVA, cerebrovascular accident; SD, standard
deviation.
TABLE 3. Univariate and multivariate analyses of preoperative
variables with overall mortality
Variable Univariate P value
SV and dialysis <.0005
Creatinine>1.5 mg/dL .005
Dialysis <.0005
Ventricular assist and dialysis <.0005
Ventricular assist and creatinine>1.5 mg/dL .006
SV and reoperation .016
Previous operations>2 .043
SV and ventricular assist .026
Bypass>3 h .068
Female sex .147
Single ventricle .224
SV and PRA>10 .395
Ventricular assist .396
Ventilator dependent .547
Donor/recipient weight ratio .603
PRA>10 and ventricular assist .636
PRA>10 .716
Age .805
Recipient weight .940
In multivariate analysis, for SVand dialysis, the odds ratio was 16.1 (95% confidence
interval, 2.3-112.1; P ¼ .005); and for creatinine>1.5 mg/dL, the odds ratio was
4.8 (95% confidence interval, 1.1-20.7; P ¼ .038). SV, Single ventricle; PRA,
panel-reactive antibody.
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received a Berlin Heart BIVAD after initial ECMO support.
Overall hospital mortality was 4.3% (n ¼ 2). Although
there were more deaths in the SV group, there was no
statistically significant difference in operative mortality
(10% SV vs 0% BV; P ¼ .2) or major morbidity (33%
SV vs 44% BV; P ¼ .55) between the 2 groups.
Risk factors associated with overall mortality by univar-
iate analysis (Table 3) were creatinine level higher than
1.5 mg/dL (P ¼ .005), dialysis (P<.0005), and 3 or more
previous sternotomies (P ¼ .043). High-risk groups
identified by univariate analysis were patients with an SV
diagnosisþ dialysis (P<.0005) (Figure 1, A), SV diagnosis
þ reoperation greater than 2 (P ¼ .016) (Figure 1, B), SV
diagnosis þ VAD (P ¼ .026) (Figure 1, C), or VAD/
ECMO þ renal insufficiency (P ¼ .006)/VAD/ECMO þ
dialysis (P<.0005) (Figure 2, A and B) (Table 3). By using
multivariate analysis, the composite of SV þ dialysis was a
predictor of overall mortality (P < .0005) (Figure 2).
Although survival at 2 years was lower in the SV cohort
(73% vs 96%; P ¼ .16), this benefit was not apparent
(63% vs 69%) at late follow-up (Figure 3).890 The Journal of Thoracic and Cardiovascular SurgDISCUSSION
Complex congenital heart disease has been an indepen-
dent predictor of mortality after heart transplantation.2,3
Improved operative technique and postoperative care has
resulted in more children surviving complex neonatal
repairs.1 Several of these patients, particularly the complex
SV group, develop end-stage ventricular dysfunction.
Within this group of complex CHD recipients, certain
subgroups are at a particularly high risk of death after heart
transplant.
Recipients who require complex pulmonary artery
reconstructive procedures concomitant with transplant
have been at a particularly higher risk.6 Heart transplant
recipients with preexisting renal insufficiency are intuitively
at a high risk of postoperative renal failure from nephrotoxic
immunosuppressive therapy. Preoperative renal insuffi-
ciency has been consistently associated with increased
posttransplant morbidity and mortality.6,7 In our study,
we found that renal insufficiency and the composite SV þ
dialysis were independent predictors of overall mortality.
Concomitant heart-renal transplant in carefully screened
and selected recipients may help improve outcomes in
patients with end-stage heart disease from CHD and
significant preoperative renal insufficiency.8,9 Combined
heart-kidney transplant should, therefore, be considered a
viable therapeutic option in this high-risk subgroup.
Elevated PRA levels in these high-risk recipients
contribute to a prolonged time on the waiting list andery c October 2013
FIGURE 1. A, Survival in patients with single-ventricle (SV) diagnosis and preoperative dialysis. B, Survival in patients with SV diagnosis and reoperation
(>2). C, Survival in patients with SV diagnosis and mechanical support. Vent Assist, Ventricular assistance.
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previous multicenter study from the United Network of
Organ Sharing (UNOS) database, our analysis did not find
elevated PRA levels to be predictive of mortality. In
addition, other individual risk factors (ie, need for
preoperative mechanical support or SV diagnosis) were
not predictive of mortality.
Previous studies have found that SV diagnosis is
associated with poor outcomes.12 Multicenter studies
from the Pediatric Heart Transplant Study group found
that a previous Fontan procedure was a risk factor for
reduced survival, particularly early after heart trans-
plant.13,14 However, contrary to these reports, others
have found comparable outcomes within the SV
subgroup and Fontan patients.15,16 In our recipients with
CHD undergoing heart transplant, we did not find SV
diagnosis, previous bidirectional Glenn, or previous
Fontan procedure to be associated with mortality. Both
operative deaths in our series were in the SV group
(10% vs 0%). However, the differences noted in early
and 2-year mortality were less apparent at late follow-
up. This could reflect the steady attrition observed with
heart transplant recipients, regardless of their initial diag-
nosis. We found that, although SV diagnosis alone was not
associated with poor outcomes, the combination of SV pa-
tients with 3 or more prior sternotomies, SV patients who
required preoperative dialysis, or those who required pre-
operative mechanical support were strongly associated
with mortality. SV patients who required preoperativeThe Journal of Thoracic and Cadialysis were specifically predictive of mortality by multi-
variate analysis.
The need for mechanical support before transplant has
been associated with poor posttransplant outcomes.17,18
However, most patients in these studies received ECMO
as mechanical support, which is an established predictor
of mortality.19 In a UNOS database study, children
requiring preoperative VAD support had similar early and
long-term survival as those not requiring VAD support. In
our series, we found that, as an individual risk factor,
mechanical support (which included ECMO and VAD)
did not incur an increased risk for death after transplant.
On the other hand, patients who received VAD support
and developed renal insufficiency and/or needed dialysis
were at a significantly higher risk of death. Similarly, we
found that SV patients who required VAD/ECMO support
were also at an increased risk for death after heart
transplant. There is evidence that mechanical support
instituted appropriately and in a timely manner improves
end-organ function and has optimized outcomes after heart
transplant.19
The short-term shortage in donor organs for adult heart
transplantation prompted the development of alternate lists
for high-risk recipients, using donor organs that would
conventionally be turned down.20 Controversy surrounds
the use of these alternate lists in heart transplantation.
Intuitively, these alternate lists could result in higher
mortality and resource use.21 However, acceptable out-
comes have been demonstrated.20 Because complexrdiovascular Surgery c Volume 146, Number 4 891
FIGURE 2. A, Survival in patients with VAD and preoperative renal
insufficiency. B, Survival in patients with VAD and dialysis. Creat,
Creatinine.
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group, alternate lists could potentially result in better
allocation of donor hearts, matching borderline donors
with high-risk recipients. This would expand the limitedFIGURE 3. Overall survival, single versus double ventricle.
892 The Journal of Thoracic and Cardiovascular Surgdonor pool and theoretically match the good donor organs
with standard-risk recipients. Although alternate lists have
been suggested for high-risk patients with congenital heart
disease, they have yet to be developed. To effectively use
alternate lists, objective and accurate identification of
groups at increased risk is essential. A previous study
identified individual risk factors that were independantly
associated with mortality.5 The study concluded that
avoiding matching high-risk donors with high-risk
recipients, as recommended by alternate lists, could
actually reduce morbidity and mortality after pediatric
heart transplantation.
Identification of specific composite high-risk groups
would certainly help in developing criteria that could be
used to either exclude high-risk recipients from receiving
standard organs or match these recipients with borderline
donors. Davies and colleagues6 demonstrated that
increasing numbers of high-risk criteria resulted in a
cumulative increase in mortality. We found similar results
with certain unique composite risk factor groups that were
predictive of mortality. We found no significant differences
between SV and BV groups, except for more previous
sternotomies and longer bypass times. SV diagnosis,
donor-recipient weight ratio, and other individual factors
were not independantly associated with mortality. Pre-
operative renal failure, the need for dialysis, and 3 or
more previous sternotomies were associated with mortality.
In contrast, when composite risk group analyses were
performed, we identified composite risk factor groups that
were strong predictors of mortality. Preoperative renal
insufficiency and SV with dialysis were strongly predictive
of overall mortality and identified high-risk congenital heart
transplant recipients.
Our study is limited by its retrospective nature and the
small sample size. Longer follow-up would also be
essential to evaluate the long-term impact of these compos-
ite risk factor groups. Another shortcoming of this study is
our definition of renal failure. We defined this as a
creatinine level higher than 1.5 mg/dL and/or need for
dialysis to identify a clinically significant degree of renal
insufficiency compared with both the Risk, Injury, Failure,
Loss, End-stage renal disease and Acute Kidney Injury
Network criteria,22 which include mild degrees of renal in-
sufficiency that are often not clinically significant. Further-
more, most patients did not have a urinary catheter placed
preoperatively to allow for accurate urine output and
creatinine clearance assessment, which are essential
elements of these renal failure scores. We did not use
oliguria as a criterion because it is not unusual for our
patients to have borderline urine output for the first
16 to 24 hours posttransplant.
In conclusion, at medium-term follow-up, although
individual risk factors were not strong predictors of
outcome, a composite of risk factors may be more usefulery c October 2013
Kavarana et al Cardiothoracic Transplantationin identifying the high-risk recipient. This, in turn, could
help improve the allocation of donor organs and overall out-
comes in heart transplantation for congenital heart disease.References
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